Overview

Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19

Status:
Suspended

Trial end date:
2020-06-30

Target enrollment:

Participant gender:

Summary

This is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg BID on D1 and 400 mg/day on D2 to D5) and azithromycin (500 mg/ 5 days) to treat moderate to severe COVID-19 pneumonia.

Phase:

Early Phase 1

Details

Lead Sponsor:

Azidus Brasil

Collaborator:

PREVENT SENIOR PRIVATE OPERADORA DE SAÚDE LTDA

Treatments:

Azithromycin
Hydroxychloroquine